NCT00345163已完成2 期
A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 167
- 主要终点
- Objective response, as determined by the independent review facility (IRF)
研究概览
简要总结
This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2 (bevacizumab + irinotecan).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form
- •Age ≥ 18 years
- •Histologically confirmed GBM in first or second relapse
- •Radiographic demonstration of disease progression following prior therapy
- •Bi-dimensionally measurable disease with a minimum measurement of 1 cm (10 mm) in one diameter on MRI performed within 14 days prior to first treatment (Day 0)
- •An interval of ≥ 4 weeks since prior surgical resection
- •Prior standard radiation for GBM
- •Prior chemotherapy: first-relapse subjects
- •Prior chemotherapy: second-relapse subjects
- •Recovery from the effects of prior therapy, including the following: 4 weeks from cytotoxic agents (except 6 weeks from nitrosoureas, 3 weeks from procarbazine, 2 weeks from vincristine); 4 weeks from any investigational agent; 1 week from non-cytotoxic agents; 8 weeks from radiotherapy to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as progression of disease, or 4 weeks if a new lesion, relative to the pre-radiation MRI, develops that is outside the primary radiation field
- •Prior therapy with gamma knife or other focal high-dose radiation is allowed but the subject must have subsequent histologic documentation of recurrence, unless the recurrence is a new lesion outside the irradiated field
- •Karnofsky performance status ≥ 70
- •Life expectancy > 12 weeks
- •Use of an effective means of contraception in males and in females of childbearing potential
- •Ability to comply with study and follow-up procedures
排除标准
- •Prior treatment with irinotecan, bevacizumab, or another VEGF or VEGFR-targeted agent
- •Prior treatment with prolifeprospan 20 with carmustine wafer
- •Prior intracerebral agents
- •Need for urgent palliative intervention for primary disease (e.g., impending herniation)
- •Evidence of recent hemorrhage on baseline MRI of the brain with the following exceptions: Presence of hemosiderin; Resolving hemorrhagic changes related to surgery; Presence of punctate hemorrhage in the tumor
- •Received more than two treatment regimens for Grade III and/or Grade IV glioma
- •Blood pressure of > 150 mmHg systolic and > 100 mmHg diastolic
- •History of hypertensive encephalopathy
- •New York Heart Association (NYHA) Grade II or greater CHF
- •History of myocardial infarction or unstable angina within 6 months prior to Day 0
- •History of stroke or transient ischemic attack within 6 months prior to study enrollment
- •Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 0
- •Evidence of bleeding diathesis or coagulopathy
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
- •History of intracerebral abscess within 6 months prior to Day 0
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
- •Minor surgical procedures (excluding placement of a vascular access device), stereotactic biopsy, fine needle aspirations, or core biopsies within 7 days prior to Day 0
- •Serious non-healing wound, ulcer, or bone fracture
- •Pregnancy (positive pregnancy test) or lactation
- •Known hypersensitivity to any component of bevacizumab
- •History of any other malignancy within 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
- •Pregnant or nursing females
- •Unstable systemic disease, including active infection, uncontrolled hypertension, or serious cardiac arrhythmia requiring medication
- •Subjects unable to undergo an MRI with contrast
研究组 & 干预措施
1
Experimental
干预措施: bevacizumab (Drug)
2
Experimental
干预措施: bevacizumab (Drug)
2
Experimental
干预措施: irinotecan (Drug)
结局指标
主要结局
Objective response, as determined by the independent review facility (IRF)
时间窗: Complete response or partial response, determined on two consecutive assessments ≥4 weeks apart
Progression-free survival, as determined by the IRF
时间窗: 6 months
次要结局
- Duration of objective response, as determined by the IRF(Complete or partial response determined on two consecutive assessments ≥4 weeks apart)
- Overall survival(Time from randomization to death)
- Incidence of adverse events and serious adverse events(Length of patient on study)
研究者
相似试验
已完成
2 期
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEIDiabetes Mellitus, Type 2Exocrine Pancreatic InsufficiencyNCT02370537AstraZeneca490
尚未招募
2 期
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1Non Small Cell Lung CancerMelanomaNCT04250246Italian Network for Tumor Biotherapy Foundation184
终止
2 期
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)Squamous Cell Carcinoma of Head and NeckNCT05061420Sanofi59
招募中
2 期
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaRelapsed/Refractory Large B-cell LymphomaNCT06414148Peter MacCallum Cancer Centre, Australia40
已完成
2 期
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.Leukemia, Myeloid, AcuteNCT02450877Celgene7